Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Aviv Regev
Broad Institute, Inc., Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Celsius Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Celsius' goal is to develop new therapies for complex disease by leveraging each tissue’s complexity within a new model for drug discovery and development. Celsius will leverage single cell genomics, computational analysis, and genetic manipulation to discover and validate novel drug targets. The company will then screen for drug candidates, and pursue them through pre-clinical and clinical development. Initial disease focus will be on cancer and autoimmune.
Celsius will use these technologies to develop therapeutics. The Regev lab will continue to develop and use similar technologies and will publish on them and make them freely available to the research community. They do not plan to work on specific therapeutic targets which is the focus of the company.
Clinical implementation of single cell tumor transcriptome analysis
Tumors are made of diverse cells. However, current technologies for measuring genes and their expression in tumors, in particular for those with therapeutically important genetic alterations, average measurements from all cells, and, thus, cannot read out information that is crucial to guide cancer precision medicine. This proposal aims to overcome these challenges by applying a new technology (single-cell transcriptome sequencing) that measures gene expression (and genetic) changes present in hundreds of individual cells extracted from tumor tissue. By implementing this technology as a clinical research tool, we will improve our ability to understand drug actions, dissect tumor response and drug resistance mechanisms, and develop new treatment strategies.
Filed on May 24, 2018.
Tell us what you know about Aviv Regev's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.